Core Viewpoint - Xinguang Pharmaceutical (300519.SZ) reported its Q3 2025 results, highlighting a decrease in institutional investor holdings and a stable presence of public funds and foreign investments [1] Institutional Holdings - As of October 27, 2025, three institutional investors disclosed holdings in Xinguang Pharmaceutical, totaling 26.0257 million shares, which represents 16.27% of the company's total equity [1] - The institutional holding percentage decreased by 2.47 percentage points compared to the previous quarter [1] Public Fund Activity - In this reporting period, 52 public funds were disclosed, including notable funds such as Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund and Huaxia CSI 500 Index Enhanced A [1] Social Security Fund - One new social security fund was disclosed, specifically the招商基金管理有限公司-社保基金1903组合 [1] Foreign Investment - One new foreign institution disclosed holdings, namely 中信证券资产管理(香港)有限公司-客户资金-人民币资金汇入, while BARCLAYS BANK PLC was not disclosed in this period [1]

Group 1 - The core viewpoint of the news is that Dailong (002209.SZ) has seen an increase in institutional investor holdings, indicating growing confidence in the company [1] - As of August 21, 2025, 22 institutional investors disclosed holding a total of 37.93 million shares of Dailong, accounting for 19.06% of the total share capital [1] - The top ten institutional investors collectively hold 18.84% of the shares, with their combined holding ratio increasing by 5.07 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two public funds increased their holdings, accounting for 1.34% of the total [2] - A total of 18 new public funds were disclosed compared to the previous quarter, including several notable funds such as Huaxia Ruipan Taili Mixed A and the Southern CSI 500 Quantitative Enhanced Stock Initiation A [2] - One new foreign institution, UBS AG, was disclosed this quarter, while Morgan Stanley & Co. International PLC was not disclosed in the current period [2]